CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Adjuvant olaparib (Lynparza) was linked with significantly longer life free of invasive or distant illness compared to placebo among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or possibly pathogenic mutations. Global patient-reported quality of life was not significantly impacted by olaparib.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
